Tumor-promoting CAFs and tumor-restricting CAFs are likely mixed, even in a single clinical tumor, and this balance within a PDAC could be modified by several CAF-targeted approaches (i.e., Hedgehog inhibitors and anti-FAP agents), which may lead to altered clinical outcomes. The gene discussed is FAP; the disease is neoplasm.